Carbapenem-resistant Acinetobacter baumannii (CRAB) infections represent the fourth-leading cause of death attributable to antimicrobial resistance globally, but a standardized therapy is still lacking. In this narrative review we focused the antibiotic treatment of CRAB infections in view of newly β-lactam agents (NBLs) like sulbactam/durlobactam and cefiderocol, discussing the main hot points such as the superiority of combination treatment over monotherapy and the best antibiotic partner to use in combination. Sulbactam/durlobactam seems to be the best candi-date to replace current back-bone agents. Cefiderocol, could play a crucial role in combina-tion-regimen. Due to toxicity and the PK/PD limitations, colistin (or polymyxin B) should be used as an alternative agent (when no other options are available). Tigecycline (or minocycline) and fosfomycin could represent suitable partners for both NBLs. Randomized clinical trials (RCTs) are needed to better evaluate the role of NBLs in CRAB infection treatment and to compare the ef-ficacy of tigecycline and fosfomycin as partner antibiotics. Synergism should be tested between NBLs and “old” drugs (rifampicin and trimethoprim/sulfamethoxazole). Huge efforts should be made to accelerate pre-clinical and clinical studies on safer polymyxin candidates with lung im-proved activity, as well as on the i.v. rifabutin formulation.

Keywords:

Subject: Medicine and Pharmacology - Epidemiology and Infectious Diseases

1. Introduction

The species belonging to Acinetobacter baumannii-calcoaceticus complex (ABC) are glucose-non-fermentative, aerobic Gram-negative coccobacilli [1]. The predominant predispositions to ABC infection are exposure to broad-spectrum antibiotics and disruption of anatomical barriers [2]. Among ABC, A. baumannii (AB) is the most common cause of human infections, responsible for a range of nosocomial infection across multiple anatomical sites, mainly ventilator-associated pneumonia (VAP) and central line-associated bloodstream infections (BSI) [3]. Peculiar findings of AB are the capacity to survive in unfavourable conditions, due to molecular features that promote environmental persistence (i.e. desiccation resistance, biofilm formation and motility) and the ability to acquire or upregulate various resistance determinants (i.e., intrinsic and acquired β-lactamases, upregulation of efflux pumps, decreased outer membrane permeability, antibiotic target site modifications) [4]. Carbapenem resistance against AB vary between 30% and 80% and is commonly associated with the horizontal transfer of genes encoding oxacillinase (OXA) carbapenemases enzymes (including OXA-23 and OXA-24/40 enzymes) [5].

Carbapenem-resistant (CR)-AB infections are the fourth-leading cause of death attributable to antimicrobial resistance globally [6], but a standardized approach to antibiotic therapy is still lacking. Current CRAB treatment guidelines agree on the use of a combination regimen for severe infections, although there are some differences in the choice of antibiotic agents [7,8] (see Table 1).

2. Considerations and Available Data about New β-Lactam Agents

2.1. Sulbactam/Durlobactam

Sulbactam/durlobactam was recently approved in U.S. for the treatment of pneumonia due to susceptible ABC [9]. Sulbactam is a class A β-lactamase inhibitor with intrinsic whole-cell activity against few bacterial species; its activity against AB is mediated through inhibition of the penicillin-binding protein (PBP)1a, PBP1b and PBP3 [12]. However, sulbactam is susceptible to cleavage by several β-lactamases, such as TEM-1, Acinetobacter-derived cephalosporinase (ADC)-30 and OXAs (OXA-23, OXA-24/72, and OXA-58 families), hence its clinical utility for AB infections has been compromised over time [13]. Durlobactam is a novel non–β-lactam diazabicyclooctane β-lactamase inhibitor, with a broad-spectrum activity against class A, C, and D β-lactamases and PBPs, resulting in intrinsic antibacterial activity against Enterobacterales and restoration of β-lactam activity in MDR Gram-negative pathogens [14]. In contrast to the other diazabicyclooctanes, durlobactam plays a crucial role in CRAB infection, due to the potent inhibition not only of class A β-lactamases but also of ADCs and OXAs, and the consequent ability to restore sulbactam activity. Furthermore, through PBP2 inhibition, it also showed a minimal intrinsic activity against the pathogen [14]. CRAB resistance to sulbactam/durlobactam was estimated to be 3.4%, mainly due to the substitution in the PBP3 determinant or the presence of New Delhi metallo-β-lactamase-1 (NDM-1); metallo β-lactamase (MBL)-producing strains are characterized by higher MIC values compared to other resistance mechanisms [15]. Although the current frequency of MBL-producing CRAB is relatively low [4,15], the commercialization of sulbactam/durlobactam may lead to an increase in the incidence of such strains, particularly NDM for which AB has been considered a reservoir [2].

Sulbactam/durlobactam demonstrated a good intrapulmonary penetration ratio for epithelial lining fluid (ELF) to total plasma concentrations in healthy subjects, supporting the use of the combination in the treatment of pulmonary infections [16]. The ATTACK trial compared sulbactam/durlobactam (1g/1g over 3 hrs infusion q6h for 7-14 days) with colistin (2.5 mg/kg over 30 min infusion q12h for 7-14 days) for severe CRAB infection (mainly pneumonia, including VAP); both regimens where co-administered with imipenem/cilastatin as background therapy: sulbactam/durlobactam resulted non-inferior to colistin in 28-day all-cause mortality -19% (12/63) vs 32% (20/62)-, presenting less adverse events (mainly nephrotoxicity, headache, nausea, and injection-site phlebitis) with respect to the competitor [17].

Co-administration of imipenem/cilastatin to provide coverage for eventual polymicrobial infections has raised questions about a possible synergic action of imipenem with sulbactam/durlobactam on CRAB, casting doubts on the real efficacy of the new β-lactam agent as monotherapy [18]. In-vitro data on CRAB isolates of ATTACK trial, seems to indicate that imipenem does not provide a meaningful contribution to sulbactam–durlobactam activity against sulbactam–durlobactam-susceptible isolates [19], however a study conducted on 109 CRAB isolates in Greece showed that the addition of imipenem further lowered the MIC90 of sulbactam/durlobactam by one two-fold dilution [20]. Currently there are not ongoing trials on sulbactam/durlobactam [21].

The encouraging data seem to place sulbactam/durlobactam as a crucial player in CRAB infection, although two relevant clinical questions are still outstanding:

1) What is the best antibiotic partner to use in combination with sulbactam/durlobactam in CRAB infections?

2) Is sulbactam/durlobactam best used in combination treatment rather than monotherapy in CRAB infections?

In our opinion, studies addressing the first question should be prioritized for the following reasons: i) the ATTACK trial tested sulbactam/durlobactam in combination regimen, and the real role of imipenem addition has not yet been clearly elucidated; ii) although there is no clear evidence of the superiority of combination treatment over monotherapy in CRAB infection, currently the main guidelines agree on the use of combination treatment (at least for severe infections) [7,8]; iii) the delay in placing in therapy of cefiderocol in CRAB infections has been essentially due to unsatisfactory clinical results in trials testing the drug as monotherapy [22,23].

It would therefore be more prudent and appropriate, in our opinion, to prioritize the search for the best antibiotic partner of sulbactam/durlobactam and, subsequently, compare monotherapy vs combination treatment.

2.2. Cefiderocol

Cefiderocol is a novel catechol-substituted siderophore cephalosporin, commercialized for the treatment of infections caused by CR Gram-negative bacteria (CR-GNB). Its activity is expressed through the inhibition of PBPs (primarily PBP3) and is transported into the periplasmic space mainly through the bacterial siderophore iron uptake system [24]. The unique structure of cefiderocol, along with low catalytic efficiencies of carbapenemases against this drug, confers stability against all four Ambler classes of β-lactamases [25]. Cefiderocol susceptibility rate for CRAB was estimated to be between 77.9% and 97.2% across different countries [25]. In the SIDERO surveillance program, 3.9% (204 out of 5225) of CRAB isolates had high (≥8 µg/mL) cefiderocol MICs without prior exposure to this antibiotic [26]: the β-lactamases Pseudomonas-extended resistance (PER) enzyme, was detected in most of these isolates [25]. Although PER (and, to a lesser extent, NDM) contributes to increasing the cefiderocol MIC of AB, it does not alone confer resistance to the drug; cefiderocol-resistance seems, in fact, to be mediated by the concomitant presence of other factors (such as PBP-3 modification, reduced expression of the siderophore receptor and efflux overexpression) [27].

The phenomenon of heteroresistance among CRAB isolates, defined as presence of resistant subpopulations at a frequency of ≥1 in 106, was investigated on 108 isolates in U.S: while the resistance rate was 8%, 64 isolates (59%) resulted heteroresistant; the frequency of resistant subpopulations increased after exposure to cefiderocol and decreased after removal from the drug [28]. The authors of the survey hypothesized that heteroresistance could explain discrepancy between the excellent in-vitro susceptibility profile and the suboptimal clinical outcomes when used as monotherapy against CRAB [28]. However, no clinical data supports this hypothesis, therefore the real clinical impact of heteroresistance is yet unclear [29].

Cefiderocol showed an effective lung penetration in healthy subjects as well as in patients with pneumonia requiring mechanical ventilation [27]. The probability of target attainment (PTA) for 100% fT>MIC was >90% across all infection sites for pathogens with cefiderocol MICs of ≤4 µg/mL; adequate plasma exposure can be achieved at the drug recommended dosing regimen (2g over 3 hrs infusion q8h) for the infected patients [30].

Despite the in-vitro efficacy and PK/PD characteristics, clinical results on cefiderocol monotherapy were unsatisfactory [22,23]. The CREDIBLE-CR trial compared cefiderocol with the best available treatment (BAT) for CR-GNB: in the subgroups of patients with CRAB, all-cause mortality at day 28 (+/- 3 days) after the end of treatment was 49% (19/39) in patients treated with cefiderocol vs 18% (3/17) in those treated with BAT, however baseline risk for mortality was higher in the cefiderocol group and BAT was largely heterogenous [22]. The APEKS-NP trial compared cefiderocol with meropenem (high-dose, extended-infusion) for the treatment of Gram-negative nosocomial pneumonia: all-cause mortality in patients with CRAB infection at day-14 were 12.4% (18/145) vs 11.6% (17/146) in the cefiderocol and meropenem groups, respectively [23].

A prospective, observational, single-centre study compared the clinical failure (defined as the need to switch to second-line antibiotic therapy due to lack of clinical response or recurrence of VAP up to 7 days from the end of active therapy) between cefiderocol and colistin-based regimen groups, in non-COVID-19 ICU patients with CRAB [31]. Cefiderocol was administered as combination treatment in 52.5% (21/40) of the cases, as monotherapy in the remaining 19 cases. Multivariable Cox regression analysis showed that first-line cefiderocol-based regimen was an independent protective factor in clinical failure risk (HR 0.38, 95% CI 0.18–0.76, p = 0.007), result confirmed through the IPTW analysis. However, there was no significant difference in 28-day all-cause mortality between groups: 35% (14/40) vs 52% (26/50) in cefiderocol and colistin-regimen groups, respectively [31]. Four Italian retrospective studies compared cefiderocol with colistin-based regimen in ICU patients with CRAB [10,11,32,33] (seeTable 2)

Two of them showed a similar rate of all-cause mortality (at days 28 and 30, respectively) between treatment groups [32,33], while in the others the cefiderocol-based regimen was an independent predictor of 30-day survival [10,11].

In a recent study aimed at evaluating the clinical efficacy of cefiderocol-based regimens for the treatment of CRAB infections, a meta-analysis was conducted on the available data (five abovementioned observational studies and the CREDIBLE-CR trial): it was demonstrated a trend towards a significantly lower mortality rate in patients received cefiderocol-based compared to colistin-based regimen [34]. Interestingly, after excluding studies at high/severe risk of bias and considering only studies performing proper adjustments for confounders, cefiderocol-based regimens were associated with a significantly lower risk of mortality (N= 4; OR 0.53; 95% CI 0.39-0.71; I2 =0.0%) [34]; however, the number of included studies was limited. Unfortunately, no subgroup analysis according to cefiderocol mono- or combination therapy was performed due to a lack of available adjusted data [34]. Anyhow, it is interesting to note that among the mentioned four retrospective studies [10,11,29,30], cefiderocol was an independent predictor of 30-day survival in the studies were the rate of cefiderocol combination-regimen was higher (see Table 2). Furthermore, in the study by Falcone et al, the microbiological failure rate was significantly higher in patients who received monotherapy compared to those who received combination therapy -42.9% (6/14) vs 6.3% (2/32)- and four patients with microbiological failure developed resistance to cefiderocol [10].

The conflicting data between the CREDIBLE-CR trial and observational studies could be explained, net of the biases already described, by the fact that in real-world studies cefiderocol was administered more frequently in combination treatment. A lower efficacy in monotherapy could in turn be explained by the phenomenon of heteroresistance. Therefore, the real clinical impact of cefiderocol-heteroresistance needs to be investigated.

While available data discourage the use of cefiderocol monotherapy in CRAB infections, real-world data on its use as a back-bone agent in combination treatment are encouraging. To accelerate the right placement in therapy of such compound, priority should be given to studies that address the following questions:

1) Is there a role for cefiderocol as back-bone agent in combination treatment for CRAB infections?

2) What is the best antibiotic partner to use in combination with cefiderocol in CRAB infections?

A trial comparing cefiderocol + ampicillin-sulbactam vs. colistin +/- meropenem for CRAB infections is currently registered, although not yet recruiting (NCT05922124) [21].

Of interest, a case of VAP due to extremely-drug-resistant (XDR)-AB successfully treated with cediferocol + sulbactam/durlobactam has been reported [35]. Probably, rather than as a combination partner for sulbactam/durlobactam, cefiderocol might be better used as an alternative back-bone regimen when sulbactam/durlobactam is contraindicated (i.e. resistance or intolerance). As a matter of fact, cefiderocol is the only known option against MBL-CRAB. A cefiderocol-sparing approach could prove to be a winning strategy in case of an increase in the rate of CRAB resistance to sulbactam/durlobactam, an event that is likely to occur after the drug's worldwide commercialization.

Randomized clinical trials (RCTs) to evaluate the efficacy of these two NBLs in combination treatment for CRAB infections are urgently needed.

3. Place in Therapy of Traditional Agents for Treatment of CRAB

3.1. Polymyxins

Colistin, available intravenously as the prodrug colistimethate sodium, and polymyxin B have been the most commonly used therapeutic options for CRAB [36]. Despite colistin resistance was uncommon in AB, there has recently been a worldwide increase in resistance rate, reaching a peak of approximately 10% in Europe [37].

Polymyxins lung penetration is suboptimal, furthermore colistin has several disadvantages compared to polymyxin B in terms of pharmacokinetic characteristic: due to the prodrug administration, colistin plasma concentration rises slowly, is subjected to a greater inter-patient variability and, in patients with normal renal function, the target plasma concentration is difficult to achieve [38]. Therefore, except for urinary tract infections (UTIs), polymyxin B is preferred to colistin for severe infections [38], however its availability is limited globally. On the contrary, colistin is preferred in UTIs due to its higher urinary concentration (polymyxin B is extensively reabsorbed by the renal tubular cells) [39], moreover it seems to present fewer side effect than polymyxin B when administered by inhalation [40]. However, data on the real clinical utility of polymyxins inhalation in patients with CRAB pneumonia are conflicting [40], as are the recommendations of professional societies [8,9,38]. The main adverse effect of polymyxins administration is nephrotoxicity, which in some reports reaches the rate of 55%, while neurotoxicity is less common [40].

Although the combination of colistin with other antibiotics (rifampicin, fosfomycin, meropenem), produced in-vitro synergistic effect against AB, clinical trials failed to demonstrate improved efficacy of colistin in combination with these antibiotics compared to monotherapy [41,42,43]. Several safer polymyxin candidates, with improved activity (also in term of lung penetration) compared to colistin and polymyxin B, are undergoing preclinical and clinical evaluations [39]. Until their commercialization, it would be appropriate, in our opinion, to use polymyxins as alternative anti-CRAB agents (when no other options are available).

3.2. Tetracycline Derivatives

Tigecycline and minocycline, capable of escaping common tetracycline resistance mechanisms, are current recommended for CRAB infections treatment [7,8]. Clinical breakpoints for tigecycline against Acinetobacter spp. have not been established [8], while the susceptibility rate to minocycline is about 85%, dropping to around 70% for multi-drug resistant (MDR) isolates [44].

Although minocycline seems to have better lung penetration than tigecycline [45,46], both compounds are characterized by suboptimal exposures in blood and serum [5]. Therefore, high-doses administration is recommended for CRAB infections [7,8]. However, in a PTA analysis, high-dose minocycline regimen currently employed in clinical practice was predicted to result in a suboptimal plasma ƒAUC:MIC profile for patients with AB infections with MICs >1 mg/l; among MDR-ABC, minocycline MIC values were >1 mg/l for 60% of the tested isolates [45]. Such data would call into question the current susceptibility breakpoint for minocycline (≤4 mg/l), based on the rat pneumonia model [45]. Furthermore, the global availability of intravenous minocycline formulation is limited. Regarding the PK/PD data on high-dose tigecycline, a study on serum and ELF concentrations among critically ill patients was conducted: PK/PD target attainment for pneumonia was ≥ 75% with MICs ≤0.5 mcg/mL [46], but only 31% of international CRAB isolates demonstrated tigecycline MICs ≤0.5 [33].

However, in-vitro synergism between tigecycline and cefiderocol has been demonstrated among both cefiderocol-resistant and susceptible CRAB isolates [47]; moreover, in observational studies, tigecycline was one of the most frequently administered agents in cefiderocol-combination regimen [34]. Tigecycline (or minocycline where iv formulation is available) could represent a suitable partner for both NBLs in CRAB infections treatment. RCTs are needed to confirm this hypothesis.

Preclinical and clinical data on the novel tetracycline derivatives, eravacycline and omadacycline, suggest reduced activity against CRAB compared to tigecycline and minocycline [8], however data are scarce and further studies are necessary to understand if and what role they may have in CRAB infections.

3.3. Fosfomycin

Fosfomycin is characterized by good tissue penetration (including infected lung tissue) as well as a good concentration in serum, urine, and cerebrospinal fluid, with a good safety profile [48]. ABC is intrinsically resistant to fosfomycin, however it resulted in a synergistic effect in-vitro when combined with several antibiotics against CRAB [48,49].

Due to a single trial which failed to demonstrate the superiority of colistin plus fosfomycin over colistin alone [43], but also because intravenous fosfomycin is not available in U.S, its role in CRAB treatment has been under-investigated [49] and the drug is not currently recommended in such infections [7,8]. Anyhow, in a prospective, observational, multicenter study, conducted on 180 patients with HAP due to MDR-AB, 44 patients were treated with a fosfomycin-containing regimen (29 in double and 15 in triple combination regimen) which turned to be a factor associated with 30-day survival (p < 0.001) [50]; moreover, in a case-series study conducted on 20 ICU patients with BSI due to pan-drug resistant (PDR)-AB, a fosfomycin-containing regimen (1 case in double regimen and 7 cases in regimens including at least three antibiotics) was associated with 28-day survival (p < 0.005) [51].

Regarding the potential role as a partner for NBLs, in-vitro data showed a synergistic effect of fosfomycin in combination with cefiderocol against a cefiderocol-resistant CRAB isolate [52]. Furthermore, in observational studies, fosfomycin was the most frequently administered agent in cefiderocol-combination regimen [34].

Interestingly, in one of the abovementioned retrospective study, fosfomycin was co-administered in 14 out 19 patients of the cefiderocol-group, resulting an independent factor of 30-day survival (p < 0.001), however 8 out of 14 patients received fosfomycin in a combination of at least three antibiotics [11].

Finally, a study conducted on sulbactam-resistant CRAB isolates in a hollow-fiber infection model showed that a combination of fosfomycin and extended infusion of sulbactam produced a 4 log₁₀ reduction in colony count within 24 h, followed by suppression of regrowth [53]. Although fosfomycin is not currently recommended, it could represent a suitable partner for both NBLs in CRAB infections treatment. RCTs are needed to confirm this hypothesis.

3.4. High-Dose Extended-Infusion Meropenem

High-dose extended-infusion meropenem regimen enhances the PK exposure of the compound but, considering the high meropenem MIC values of CRAB isolates, does not reach the optimal cumulative fraction of response in such infections [54]. However, triple combination regimen containing meropenem has been used successfully for XDR-CRAB infections [5] and, in one case, meropenem was co-administered with cefiderocol [55].

Interestingly, cefiderocol + meropenem demonstrated in vitro synergistic effect against 79.5% of cefiderocol-resistant isolates [47]. A case of PDR-CRAB infection was cured with a combination of sulbactam/durlobactam + meropenem; of note, the addition of meropenem reduced the sulbactam/durlobactam MIC from 8 to 4 mg/L (the preliminary susceptibility breakpoint) [56]. If further studies will confirm the synergism between meropenem and NBLs, high-dose extended-infusion meropenem + sulbactam/durlobactam (or cefiderocol) could represent a valuable option for PDR-CRAB infections.

From this perspective, a meropenem-sparing strategy should be adopted in case of CRAB infections due to strains sensitive to the NBLs. In case of co-administration of high-dose meropenem with another β-lactam a close monitoring of side effects should be warranted, due to the high probability of an increase in toxicity rate.

3.5. Aminoglycosides

Aminoglycosides are currently recommended in combination treatment for susceptible CRAB isolates [7], however global resistance rate is >80% [37]. Furthermore, considering drugs’ side effects [57] and suboptimal ELF concentrations [58], their prospective role in CRAB infections will likely be limited to a few selected cases.

3.6. Rifamycins

Rifampicin showed synergistic effect against MDR-AB when combined with colistin [59], but the clinical efficacy of such treatment has not been demonstrated [42] and rifampicin is currently not recommended in CRAB infections [7,8]. However, in-vitro synergism seems to depend by rifampicin MICs, and data on rifampicin MIC values of CRAB isolates are scant [59].

Interestingly, in-vitro synergism between rifampicin and sulbactam against CRAB isolates has been demonstrated [60]; moreover, in a case series on 12 infant and young children with severe VAP caused by XDR-AB, the combination of rifampicin and sulbactam appeared to be an effective and safe therapy (9 out of 12 patients were considered cured) [61]. Studies addressing in-vitro synergic effect between rifampicin and the NBLs should be conducted, eventually followed by clinical evaluations of combined treatments.

Rifabutin, available only as an oral formulation, overcomes the common rifamycin resistance mechanisms of AB, displaying potent in-vitro activity against CRAB strains [62]. The drug is rapidly distributed in all organs and tissues, where levels are constantly higher than plasma levels; unfortunately, the oral bioavailability of rifabutin is very low, limiting its clinical utility [62]. An intravenous formulation of rifabutin (BV100) has been developed to maximize clinical efficacy against AB infections while minimizing the risk of resistance development, and it is currently under investigation in a Phase I clinical trial [62].

3.7. Trimethoprim/Sulfamethoxazole

Sporadic cases of MDR-AB have been successfully treated with a combination regimen including trimethoprim/sulfamethoxazole [11,63], while in a retrospective match cohort study, comparing trimethoprim/sulfamethoxazole monotherapy with other regimens for CRAB infections, all-cause 30-day mortality was lower in trimethoprim/sulfamethoxazole group (24.5%, 13 of 53 vs. 38.6%, 32 of 83), however baseline risk for mortality was higher in the comparator antibiotics group [64]. The resistance rate among CRAB isolates is estimated to be >80% [63] and trimethoprim/sulfamethoxazole is currently not recommended for such infections [8,9].

Possible synergistic effects between trimethoprim/sulfamethoxazole and the NBLs should be investigated; the compound could represent a valuable partner in CRAB combination-treatment, at least for infections due to sensitive isolates.

4. Conclusions

The commercialization of NBLs, opens a new scenario for the treatment of CRAB infections.

However, data are limited and relevant clinical questions remain outstanding, such as the superiority of combination treatment over monotherapy and the best antibiotic partner to use in combination.

In this narrative review, we have highlighted the main characteristic and potential role of anti-CRAB antibiotics (summarized in Table 3), in view of recent data on NBLs. Sulbactam/durlobactam seems to be the best candidate to replace current back-bone agents. Cefiderocol, despite the suboptimal efficacy in monotherapy, could play a crucial role in combination-regimen (probably as an alternative back-bone agent): RCTs are needed to better evaluate the role of these new β-lactams in CRAB infections. Due to toxicity and the PK/PD limitations, colistin should be used as an alternative anti-CRAB agent (when no other options are available).

Tigecycline and fosfomycin could represent suitable partners for both NBLs: RCTs comparing the efficacy of these two drugs as partner-antibiotics in combined CRAB treatment should be prioritized [65]. High-dose extended-infusion meropenem, if further studies will confirm the synergistic effect between meropenem and NBLs, should be taken into consideration in case of PDR-CRAB infections, while the role of aminoglycosides will be probably limited to a few selected cases. In-vitro data on the synergism between NBLs and rifampicin or trimethoprim/sulfamethoxazole are needed to guide eventual any future clinical investigations into the possible role of these “old antibiotics” as partner-agents in CRAB infection treatment.

Taking in account the limitations of current available partner-antibiotic candidates for CRAB infections, huge efforts should be made to accelerate pre-clinical and clinical studies on safer polymyxin candidates with lung improved activity, as well as on the intravenous formulation of rifabutin.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable

Informed Consent Statement

Not applicable

Data Availability Statement

Not applicable.

Acknowledgments

FS and MG conceptualized and wrote the manuscript; SPG and RL wrote the manuscript; AB, EG, FL, AR and EMT revised the manuscript.

Conflicts of Interest

The authors declare no conflicts of interest

References

Peleg, A.Y.; Seifert, H.; Paterson, D.L. Acinetobacter baumannii : Emergence of a Successful Pathogen. Clin. Microbiol. Rev. 2008, 21, 538–582. [Google Scholar] [CrossRef] [PubMed]
Wong, D.; Nielsen, T.B.; Bonomo, R.A.; Pantapalangkoor, P.; Luna, B.; Spellberg, B. Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges. Clin. Microbiol. Rev. 2017, 30, 409–447. [Google Scholar] [CrossRef] [PubMed]
Harding, C.M.; Hennon, S.W.; Feldman, M.F. Uncovering the mechanisms of Acinetobacter baumannii virulence. Nat. Rev. Microbiol. 2017, 16, 91–102. [Google Scholar] [CrossRef]
Castanheira, M.; E Mendes, R.; Gales, A.C. Global Epidemiology and Mechanisms of Resistance of Acinetobacter baumannii-calcoaceticus Complex. Clin. Infect. Dis. 2023, 76, S166–S178. [Google Scholar] [CrossRef]
Shields, R.K.; Paterson, D.L.; Tamma, P.D. Navigating Available Treatment Options for Carbapenem-Resistant Acinetobacter baumannii-calcoaceticus Complex Infections. Clin. Infect. Dis. 2023, 76 (Suppl. 2), S179–S193. [Google Scholar] [CrossRef] [PubMed]
Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 2022, 399, 629–655.
Paul, M.; Carrara, E.; Retamar, P.; Tangden, T.; Bitterman, R.; Bonomo, R.A.; de Waele, J.; Daikos, G.L.; Akova, M.; Harbarth, S.; et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin. Microbiol. Infect. 2022, 28, 521–547. [Google Scholar] [CrossRef] [PubMed]
Tamma, P.D.; Aitken, S.L.; A Bonomo, R.; Mathers, A.J.; van Duin, D.; Clancy, C.J. Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. Clin. Infect. Dis. 2023, ciad428. [Google Scholar] [CrossRef] [PubMed]
US Food and Drug Administration. FDA approves new treatment for pneumonia caused by certain difficult-to-treat bacteria [media release]. Available online: https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-pneumonia-caused-certain-difficult-treat-bacteria (accessed on 23 May 2023).
Falcone, M.; Tiseo, G.; Leonildi, A.; Della Sala, L.; Vecchione, A.; Barnini, S.; Farcomeni, A.; Menichetti, F. Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 2022, 66, e0214221. [Google Scholar] [CrossRef]
Russo, A.; Bruni, A.; Gullì, S.; Borrazzo, C.; Quirino, A.; Lionello, R.; Serapide, F.; Garofalo, E.; Serraino, R.; Romeo, F.; et al. Efficacy of cefiderocol- vs colistin-containing regimen for treatment of bacteraemic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in patients with COVID-19. Int. J. Antimicrob. Agents 2023, 62, 106825–106825. [Google Scholar] [CrossRef]
Penwell, W.F.; Shapiro, A.B.; Giacobbe, R.A.; Gu, R.-F.; Gao, N.; Thresher, J.; McLaughlin, R.E.; Huband, M.D.; DeJonge, B.L.M.; Ehmann, D.E.; et al. Molecular Mechanisms of Sulbactam Antibacterial Activity and Resistance Determinants in Acinetobacter baumannii. Antimicrob. Agents Chemother. 2015, 59, 1680–1689. [Google Scholar] [CrossRef]
Kuo, S.-C.; Lee, Y.-T.; Lauderdale, T.-L.Y.; Huang, W.-C.; Chuang, M.-F.; Chen, C.-P.; Su, S.-C.; Lee, K.-R.; Chen, T.-L. Contribution of Acinetobacter-derived cephalosporinase-30 to sulbactam resistance in Acinetobacter baumannii. Front. Microbiol. 2015, 6, 231. [Google Scholar] [CrossRef]
Durand-Réville, T.F.; Guler, S.; Comita-Prevoir, J.; Chen, B.; Bifulco, N.; Huynh, H.; Lahiri, S.; Shapiro, A.B.; McLeod, S.M.; Carter, N.M.; et al. ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii. Nat. Microbiol. 2017, 2, 17104. [Google Scholar] [CrossRef]
Principe, L.; Di Bella, S.; Conti, J.; Perilli, M.; Piccirilli, A.; Mussini, C.; Decorti, G. Acinetobacter baumannii Resistance to Sulbactam/Durlobactam: A Systematic Review. Antibiotics 2022, 11, 1793. [Google Scholar] [CrossRef]
Rodvold, K.A.; Gotfried, M.H.; Isaacs, R.D.; O'Donnell, J.P.; Stone, E. Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam following Intravenous Administration of ETX2514SUL to Healthy Adult Subjects. Antimicrob. Agents Chemother. 2018, 62. [Google Scholar] [CrossRef]
Kaye KS, Shorr AF, Wunderink RG, et al. Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK). Lancet Infect Dis. 2023, 23, 1072–1084.
Giuliano, S.; Sbrana, F.; Tascini, C. Sulbactam–durlobactam for infections caused by Acinetobacter baumannii–calcoaceticus complex. Lancet Infect. Dis. 2023, 23, e274–E274. [Google Scholar] [CrossRef]
Kaye KS, McLeod SM, O'Donnell JP, Altarac D. Sulbactam-durlobactam for infections caused by Acinetobacter baumannii-calcoaceticus complex - Authors' reply. Lancet Infect Dis. 2023, 23, e275–e276.
Petropoulou, D.; Siopi, M.; Vourli, S.; Pournaras, S. Activity of Sulbactam-Durlobactam and Comparators Against a National Collection of Carbapenem-Resistant Acinetobacter baumannii Isolates From Greece. Front. Cell. Infect. Microbiol. 2022, 11, 814530. [Google Scholar] [CrossRef] [PubMed]
National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/.
Bassetti, M.; Echols, R.; Matsunaga, Y.; Ariyasu, M.; Doi, Y.; Ferrer, R.; Lodise, T.P.; Naas, T.; Niki, Y.; Paterson, D.L.; et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect. Dis. 2021, 21, 226–240. [Google Scholar] [CrossRef] [PubMed]
Wunderink, R.G.; Matsunaga, Y.; Ariyasu, M.; Clevenbergh, P.; Echols, R.; Kaye, K.S.; Kollef, M.; Menon, A.; Pogue, J.M.; Shorr, A.F.; et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect. Dis. 2021, 21, 213–225. [Google Scholar] [CrossRef]
Syed, Y.Y. Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections. Drugs 2021, 81, 1559–1571. [Google Scholar] [CrossRef]
Kollef, M.; Dupont, H.; Greenberg, D.E.; Viale, P.; Echols, R.; Yamano, Y.; Nicolau, D.P. Prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: Review of the evidence. Int. J. Antimicrob. Agents 2023, 62, 106882. [Google Scholar] [CrossRef]
Karlowsky, J.A.; Hackel, M.A.; Takemura, M.; Yamano, Y.; Echols, R.; Sahm, D.F. In Vitro Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019. Antimicrob. Agents Chemother. 2021, 66, e0199021. [Google Scholar] [CrossRef]
Poirel L, Sadek M, Nordmann P. Contribution of PER-Type and NDM-Type β-Lactamases to Cefiderocol Resistance in Acinetobacter baumannii. Antimicrob Agents Chemother. 2021, 65, e0087721.
Choby, J.E.; Ozturk, T.; Satola, S.W.; Jacob, J.T.; Weiss, D.S. Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogens. Lancet Infect. Dis. 2021, 21, 597–598. [Google Scholar] [CrossRef]
Karakonstantis, S.; Rousaki, M.; Kritsotakis, E.I. Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance. Antibiotics 2022, 11, 723. [Google Scholar] [CrossRef]
Kawaguchi, N.; Katsube, T.; Echols, R.; Wajima, T. Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients with Pneumonia, Bloodstream Infection/Sepsis, or Complicated Urinary Tract Infection. Antimicrob. Agents Chemother. 2021, 65. [Google Scholar] [CrossRef]
Dalfino L, Stufano M, Bavaro DF, et al. Effectiveness of First-Line Therapy with Old and Novel Antibiotics in Ventilator-Associated Pneumonia Caused by Carbapenem-Resistant Acinetobacter baumannii: A Real Life, Prospective, Observational, Single-Center Study. Antibiotics (Basel). 2023, 12, 1048.
Pascale, R.; Pasquini, Z.; Bartoletti, M.; Caiazzo, L.; Fornaro, G.; Bussini, L.; Volpato, F.; Marchionni, E.; Rinaldi, M.; Trapani, F.; et al. Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort study. JAC-Antimicrobial Resist. 2021, 3, dlab174. [Google Scholar] [CrossRef] [PubMed]
Mazzitelli M, Gregori D, Sasset L, et al. Cefiderocol-Based versus Colistin-Based Regimens for Severe Carbapenem-Resistant Acinetobacter baumannii Infections: A Propensity Score-Weighted, Retrospective Cohort Study during the First Two Years of the COVID-19 Pandemic. Microorganisms. 2023, 11, 984.
Gatti M, Cosentino F, Giannella M, Viale P, Pea F. Clinical efficacy of cefiderocol-based regimens in patients affected by carbapenem-resistant Acinetobacter baumannii infections: a systematic review with meta-analysis. Int J Antimicrob Agents. 2023, 107047.
Zaidan, N.; Hornak, J.P.; Reynoso, D. Extensively Drug-Resistant Acinetobacter baumannii Nosocomial Pneumonia Successfully Treated with a Novel Antibiotic Combination. Antimicrob. Agents Chemother. 2021, 65, e0092421. [Google Scholar] [CrossRef] [PubMed]
Lyu, C.; Zhang, Y.; Liu, X.; Wu, J.; Zhang, J. Clinical efficacy and safety of polymyxins based versus non-polymyxins based therapies in the infections caused by carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis. BMC Infect. Dis. 2020, 20, 1–14. [Google Scholar] [CrossRef]
Seifert, H.; Blondeau, J.; Lucaßen, K.; Utt, E.A. Global update on the in vitro activity of tigecycline and comparators against isolates of Acinetobacter baumannii and rates of resistant phenotypes (2016–2018). J. Glob. Antimicrob. Resist. 2022, 31, 82–89. [Google Scholar] [CrossRef]
Tsuji, B.T.; Pogue, J.M.; Zavascki, A.P.; Paul, M.; Daikos, G.L.; Forrest, A.; Giacobbe, D.R.; Viscoli, C.; Giamarellou, H.; Karaiskos, I.; et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacother. J. Hum. Pharmacol. Drug Ther. 2019, 39, 10–39. [Google Scholar] [CrossRef]
Nang, S.C.; Azad, M.A.K.; Velkov, T.; Zhou, Q. ; Li, J. Rescuing the Last-Line Polymyxins: Achievements and Challenges. Pharmacol. Rev. 2021, 73, 679–728. [Google Scholar] [CrossRef] [PubMed]
Kassamali, Z.; Jain, R.; Danziger, L.H. An Update on the arsenal for multidrug-resistant Acinetobacter infections: Polymyxin antibiotics. Int. J. Infect. Dis. 2015, 30, 125–132. [Google Scholar] [CrossRef] [PubMed]
Paul, M.; Daikos, G.L.; Durante-Mangoni, E.; Yahav, D.; Carmeli, Y.; Benattar, Y.D.; Skiada, A.; Andini, R.; Eliakim-Raz, N.; Nutman, A.; et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect. Dis. 2018, 18, 391–400. [Google Scholar] [CrossRef]
Durante-Mangoni, E.; Signoriello, G.; Andini, R.; Mattei, A.; De Cristoforo, M.; Murino, P.; Bassetti, M.; Malacarne, P.; Petrosillo, N.; Galdieri, N.; et al. Colistin and Rifampicin Compared With Colistin Alone for the Treatment of Serious Infections Due to Extensively Drug-Resistant Acinetobacter baumannii: A Multicenter, Randomized Clinical Trial. Clin. Infect. Dis. 2013, 57, 349–358. [Google Scholar] [CrossRef]
Sirijatuphat, R.; Thamlikitkul, V. Preliminary Study of Colistin versus Colistin plus Fosfomycin for Treatment of Carbapenem-Resistant Acinetobacter baumannii Infections. Antimicrob. Agents Chemother. 2014, 58, 5598–5601. [Google Scholar] [CrossRef]
Flamm, R.K.; Shortridge, D.; Castanheira, M.; Sader, H.S.; Pfaller, M.A. In Vitro Activity of Minocycline against U.S. Isolates of Acinetobacter baumannii-Acinetobacter calcoaceticus Species Complex, Stenotrophomonas maltophilia, and Burkholderia cepacia Complex: Results from the SENTRY Antimicrobial Surveillance Program, 2014 to 2018. Antimicrob. Agents Chemother. 2019, 63. [Google Scholar] [CrossRef]
Lodise, T.P.; Van Wart, S.; Sund, Z.M.; Bressler, A.M.; Khan, A.; Makley, A.T.; Hamad, Y.; Salata, R.A.; Silveira, F.P.; Sims, M.D.; et al. Pharmacokinetic and Pharmacodynamic Profiling of Minocycline for Injection following a Single Infusion in Critically Ill Adults in a Phase IV Open-Label Multicenter Study (ACUMIN). Antimicrob. Agents Chemother. 2021, 65. [Google Scholar] [CrossRef]
De Pascale G, Lisi L, Ciotti GMP, et al. Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections. Ann Intensive Care. 2020, 10, 94.
Ni, W.; Wang, Y.; Ma, X.; He, Y.; Zhao, J.; Guan, J.; Li, Y.; Gao, Z. In vitro and in vivo efficacy of cefiderocol plus tigecycline, colistin, or meropenem against carbapenem-resistant Acinetobacter baumannii. Eur. J. Clin. Microbiol. Infect. Dis. 2022, 41, 1451–1457. [Google Scholar] [CrossRef]
Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ. Fosfomycin. Clin Microbiol Rev. 2016, 29, 321–347.
Guastalegname, M.; Trecarichi, E.M.; Russo, A. Intravenous Fosfomycin: The Underdog Player in the Treatment of Carbapenem-resistant Acinetobacter baumannii Infections. Clin. Infect. Dis. 2023, 77, 1736–1737. [Google Scholar] [CrossRef]
Russo, A.; Bassetti, M.; Bellelli, V.; Bianchi, L.; Cattaneo, F.M.; Mazzocchetti, S.; Paciacconi, E.; Cottini, F.; Schiattarella, A.; Tufaro, G.; et al. Efficacy of a Fosfomycin-Containing Regimen for Treatment of Severe Pneumonia Caused by Multidrug-Resistant Acinetobacter baumannii: A Prospective, Observational Study. Infect. Dis. Ther. 2020, 10, 187–200. [Google Scholar] [CrossRef]
Assimakopoulos, S.F.; Karamouzos, V.; Eleftheriotis, G.; Lagadinou, M.; Bartzavali, C.; Kolonitsiou, F.; Paliogianni, F.; Fligou, F.; Marangos, M. Efficacy of Fosfomycin-Containing Regimens for Treatment of Bacteremia Due to Pan-Drug Resistant Acinetobacter baumannii in Critically Ill Patients: A Case Series Study. Pathogens 2023, 12, 286. [Google Scholar] [CrossRef]
Palombo, M.; Bovo, F.; Amadesi, S.; Gaibani, P. Synergistic Activity of Cefiderocol in Combination with Piperacillin-Tazobactam, Fosfomycin, Ampicillin-Sulbactam, Imipenem-Relebactam and Ceftazidime-Avibactam against Carbapenem-Resistant Gram-Negative Bacteria. Antibiotics 2023, 12, 858. [Google Scholar] [CrossRef]
Lim, S.M.S.; Heffernan, A.; Naicker, S.; Wallis, S.; Roberts, J.A.; Sime, F.B. Evaluation of Fosfomycin-Sulbactam Combination Therapy against Carbapenem-Resistant Acinetobacter baumannii Isolates in a Hollow-Fibre Infection Model. Antibiotics 2022, 11, 1578. [Google Scholar] [CrossRef]
Koomanachai, P.; Crandon, J.L.; Kuti, J.L.; Nicolau, D.P. Comparative pharmacodynamics for intravenous antibiotics against Gram-negative bacteria in Europe between 2002 and 2006: a report from the OPTAMA program. Int. J. Antimicrob. Agents 2009, 33, 348–353. [Google Scholar] [CrossRef]
Bavaro, D.F.; Belati, A.; Diella, L.; Stufano, M.; Romanelli, F.; Scalone, L.; Stolfa, S.; Ronga, L.; Maurmo, L.; Dell’aera, M.; et al. Cefiderocol-Based Combination Therapy for “Difficult-to-Treat” Gram-Negative Severe Infections: Real-Life Case Series and Future Perspectives. Antibiotics 2021, 10, 652. [Google Scholar] [CrossRef] [PubMed]
Holger, D.J.; Coyne, A.J.K.; Zhao, J.J.; Sandhu, A.; Salimnia, H.; Rybak, M.J. Novel Combination Therapy for Extensively Drug-Resistant Acinetobacter baumannii Necrotizing Pneumonia Complicated by Empyema: A Case Report. Open Forum Infect. Dis. 2022, 9, ofac092. [Google Scholar] [CrossRef] [PubMed]
Lopez-Novoa, J.M.; Quiros, Y.; Vicente, L.; Morales, A.I.; Lopez-Hernandez, F.J. New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int. 2011, 79, 33–45. [Google Scholar] [CrossRef]
Najmeddin, F.; Shahrami, B.; Azadbakht, S.; Dianatkhah, M.; Rouini, M.R.; Najafi, A.; Ahmadi, A.; Sharifnia, H.; Mojtahedzadeh, M. Evaluation of Epithelial Lining Fluid Concentration of Amikacin in Critically Ill Patients With Ventilator-Associated Pneumonia. J. Intensiv. Care Med. 2018, 35, 400–404. [Google Scholar] [CrossRef]
Mohammadi, M.; Khayat, H.; Sayehmiri, K.; Soroush, S.; Sayehmiri, F.; Delfani, S.; Bogdanovic, L.; Taherikalani, M. Synergistic Effect of Colistin and Rifampin Against Multidrug Resistant Acinetobacter baumannii: A Systematic Review and Meta-Analysis. Open Microbiol. J. 2017, 11, 63–71. [Google Scholar] [CrossRef] [PubMed]
Tripodi, M.-F.; Durante-Mangoni, E.; Fortunato, R.; Utili, R.; Zarrilli, R. Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases. Int. J. Antimicrob. Agents 2007, 30, 537–540. [Google Scholar] [CrossRef] [PubMed]
Chen, J.; Yang, Y.; Xiang, K.; Li, D.; Liu, H. Combined Rifampin and Sulbactam Therapy for Multidrug-Resistant Acinetobacter Baumannii Ventilator-Associated Pneumonia in Pediatric Patients. J. Anesthesia Perioper. Med. 2018, 5, 176–185. [Google Scholar] [CrossRef] [PubMed]
Trebosc, V.; Kemmer, C.; Lociuro, S.; Gitzinger, M.; Dale, G.E. Rifabutin for infusion (BV100) for the treatment of severe carbapenem-resistant Acinetobacter baumannii infections. Drug Discov. Today 2021, 26, 2099–2104. [Google Scholar] [CrossRef]
Falagas, M.E.; Vardakas, K.Z.; Roussos, N.S. Trimethoprim/sulfamethoxazole for Acinetobacter spp.: A review of current microbiological and clinical evidence. Int. J. Antimicrob. Agents 2015, 46, 231–241. [Google Scholar] [CrossRef]
Raz-Pasteur A, Liron Y, Amir-Ronen R, et al. Trimethoprim-sulfamethoxazole vs. colistin or ampicillin-sulbactam for the treatment of carbapenem-resistant Acinetobacter baumannii: A retrospective matched cohort study. J Glob Antimicrob Resist. 2019, 17, 168–172.
Russo, A.; Gullì, S.P.; D'Avino, A.; Borrazzo, C.; Carannante, N.; Dezza, F.C.; Covino, S.; Polistina, G.; Fiorentino, G.; Trecarichi, E.M. Intravenous fosfomycin for treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii: a multicenter clinical experience. Int J Antimicrob Agents 2024, 107190. [Google Scholar] [CrossRef]

Table 1. Differences between CRAB treatment guidelines.

	ESCMID guidelines (April 2022)	IDSA guidance (July 2023)
Combination antibiotic regimen	For severe and high-risk CRAB infection	For moderate-severe CRAB infection
Ampicillin/sulbactam	For patients with CRAB susceptible to sulbactam and HAP/VAP (1 g sulbactam component q6h)	Back-bone treatment for all CRAB infection (6-9 g sulbactam component daily)
Polymyxins	Either colistin or polymyxin B: for patients with CRAB resistant to sulbactam susceptible to polymyxins; in combination with one other in-vitro active agent for severe, susceptible to polymyxins, CRAB infection	Polymyxin B in combination with at least one other agent for the treatment of CRAB infections (Colistin only for CRAB UTIs)
Tetracycline derivatives	High-dose tigecycline: for patients with CRAB resistant to sulbactam susceptible to tigecycline; in combination with one other in-vitro active agent for severe, susceptible to tigecycline, CRAB infection	High-dose minocycline (preferred option) or high-dose tigecycline in combination with at least one other agent for the treatment of CRAB infections
Cefiderocol	Not recommended	In combination with at least one other agent for the treatment of CRAB infections refractory to other antibiotics (or when the use of other antibiotics is precluded)
Aminoglycosides	In combination with one other in-vitro active agent for severe, susceptible to aminoglycosides, CRAB infection	Not recommended
High-dose extended- infusion meropenem	In combination with one other in-vitro active agent for severe CRAB infections with a meropenem MIC <8 mg/L	Not recommended

Legend. CRAB: carbapenem-resistant Acinetobacter baumannii; ESCMID: European Society of Clinical Microbiology and Infectious Diseases; IDSA: Infectious Diseases Society of America;HAP: health-care associated pneumonia; VAP: ventilator-associated pneumonia; UTIs: urinary tract infections. High-dose tigecycline: 200 mg as a loading dose followed by 100 mg q12h; High-dose minocycline: 200 mg q12h. High-dose extended-infusion meropenem: 2 g over 3 hrs infusion q8h.

Table 2. Retrospective observational studies comparing cefiderocol with colistin-based regimen in ICU patients with CRAB.

	Pascale et al. [32] multicentre (Jan 2020-Apr 2021)	Mazzitelli et al. [33] single-centre (Aug 2020-Jul 2022)	Falcone et al. [10] single-centre (Jan 2020-Aug 2021)	Russo et al. [11] single-centre (Mar 2020-Aug 2022)
Population: antibiotic-based regimen groups	107 patients: 42 CFD 65 COL	111 patients: 60 CFD 51 COL	124 patients: 47 CFD 77 COL	73 patients: 19 CFD 54 COL
Covid-19 coinfection	100%	32%	38,7%	100%
Site of infection	BSI (58%) LRTI (41%) Others (1%)	BSI (47,7%) Pneumonia (52,3%)	BSI (57,4%) VAP (25,5%) Others (17%)	VAP and concomitant BSI (100%)
Patients received CFD in combination	0	30 (50%)	33 (70%)	19 (100%)
Main agents co-administered with CFD	/	TGC (18/30) MEM (13/30) FOS (8/30)	TGC (21/33) FOS (8/33)	FOS (7/19) FOS + TGC (7/19) TGC (1/19)
28-30 day all-cause mortality: CFD group vs COL group	23 (55%) vs 38 (58%) (p-value: 0,7)	26 (51%) vs 22 (37%) (p-value: 0,13)	16 (34%) vs 43 (56%) (p-value: 0.018)	6 (31.5%) vs 53 (98%) (p-value <0.001)

Legend. ICU: intensive care unit; CRAB: carbapenem-resistant Acinetobacter baumannii; CFD: cefiderocol; COL: colistin; BSI: bloodstream infection; LRTI: low respiratory tract infection; VAP: ventilator-associated pneumonia; TGC: tigecycline; MEM: meropenem; FOS: fosfomycin.

Table 3. Potential role of anti-CRAB antibiotics.

	Potential role	Evidences (or available data)	Limits	Studies to be prioritized
Sulbactam/ durlobactam	Back-bone agent in combination treatment	RCT: non-inferior to COL (both co-administered with IPM-CLN) [17]	Efficacy as monotherapy not known	RCTs finding the best partner-agent
Cefiderocol	Back-bone agent in combination treatment	Metanalysis: lower risk of mortality rate compared to COL-based regimen [34]	Unsatisfactory efficacy as monotherapy when compared to COL [22] and MEM [23]	-RCTs confirming the role as back-bone agent; -RCTs finding the best partner-agent
Polymyxins	COL (or PB): alternative agent (when no other options are available)	Large clinical experience as back-bone agent [36]. (Data on combination with NBLs are missing)	-Nefrotoxicity [40]; -suboptimal lung penetration [38]; - suboptimal plasma concentrations [38].	Accelerate studies on safer polymyxin with lung improved activity
Tetracycline derivatives	High-dose TGC (or MNC): partner-agent in combination treatment	TGC + CFD: -in-vitro synergism [47]; (one of the most frequently used combination in observational studies [34])	Suboptimal exposures in serum, lung and urine [5]	RCTs comparing TGC and FOS as partner-agent
Fosfomycin	Partner-agent in combination treatment	-Retrospective study: associated with 30-day survival in combination with CFD [11]; -In-vitro synergism with CFD [52] and SUL [53];(the most commonly used agent in combination with CFD in observational studies [34])	-Data coming from the observational study included regimens of more than 2 agents [11] -AB is intrinsically resistant to the drug [48];	RCTs comparing TGC and FOS as partner-agent
High-dose extended- infusion meropenem	Partner-agent in PDR-CRAB infections (to be spared in treatment of strains sensitives to NBLs)	In-vitro synergism against CFD-resistant strains [47]. (Combined with SUL-DUR: a single case report of PDR-CRAB cured, with in-vitro synergistic effect [56])	-Suboptimal cumulative fraction of response [54]; -possible increase in side effects rate if co-administered with other BLs	-In-vitro studies on synergism with NBLs; -Clinical studies on PDR-CRAB infections
Amino-glycosides	Alternative partner-agent for few selected cases	Currently recommended as a combination treatment for susceptible CRAB isolates [7]. (Data on combination with NBLs are missing)	-Resistance rate among CRAB isolates > 80%; -suboptimal concentration in lung [37]; - high rate side effects [57]	/
Rifamycins	Alternative partner-agent	RFM + SUL: -in-vitro synergism [60];(a case series on 12 pediatric patients reported clinical efficacy in VAP due to XDR-AB [61])	Synergism seems to depend by rifampicin MICs, but MICs data are scant [59]	-Accelerate clinical studies on rifabutin iv formulation; -in-vitro studies on synergism between RFM and NBLs
Trimethoprim/ sulfamethoxazole	Alternative partner-agent	(Successfully administered in combination with CFD in sporadic cases [11])	Resistance rate among CRAB isolates > 80% [63]	In-vitro studies on synergism with NBLs

Legend. CRAB: carbapenem-resistant Acinetobacter baumannii; RCT: randomized clinical trial; COL: colistin; IMP-CLN: imipenem/cilastatin; MEM: meropenem; PB: polymyxin B; NBLs: newly developed β-lactam agents; TGC: tigecycline; MNC: minocycline; CFD: cefiderocol; FOS: fofsomycin; SUL: sulbactam; AB: Acinetobacter baumannii; PDR: pan-drug resistant; DUR: durlobactam; BLs: β-lactam agents; RFM: rifampicin; VAP: ventilator-associated pneumonia; XDR: extremely-drug resistant; MICs: minimal inhibitory concentrations. High-dose tigecycline: 200 mg as a loading dose followed by 100 mg q12h; High-dose minocycline: 200 mg q12h; High-dose extended-infusion meropenem: 2 g over 3 hrs infusion q8h.

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

MDPI Initiatives

Important Links

Choose an area of interest and we will send you notifications of new preprints at your preferred frequency.

Disclaimer

Antibiotic Treatment of Carbapenem-Resistant Acinetobacter baumannii Infections in View of the Newly Developed β-Lactams: A Narrative Review of the Existing Evidence

Abstract